Other
Neoplasm by Site
CI-CAN-00000003Explore in graph →
Non-malignant20,485 active trials253 approved drugs3,567 evidence items
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000003Explore in graph →
Clinical trials
92,566 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00712621 | Determining Quality of Life in Breast Cancer Patient After Completing Radiation,Chemotherapy,Surgery or Combination | withdrawn | Phase 2 | 460 | American Scitech InternationalOTHER | 1 | Nov 24, 2009 | clinicaltrials |
| NCT00610792 | Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens | withdrawn | Phase 2 | 91 | Millennium Pharmaceuticals, Inc.INDUSTRY | 2 | Jul 14, 2009 |
| NCT00540332 | A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer Receiving Postoperative Radiotherapy | withdrawn | Phase 1 / Phase 2 | 0 | Swedish Orphan BiovitrumINDUSTRY | 0 | Mar 2, 2009 | clinicaltrials |
| NCT00209612 | Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC. | withdrawn | Phase 1 / Phase 2 | 40 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | Feb 17, 2009 | clinicaltrials |
| NCT00485966 | Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia | withdrawn | Phase 2 | 25 | Cylene PharmaceuticalsINDUSTRY | 1 | Nov 5, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00380835 | Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer | withdrawn | Phase 2 | 66 | Celgene CorporationINDUSTRY | 1 | Sep 23, 2008 | clinicaltrials |
| NCT00676871 | A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL) | withdrawn | Phase 1 / Phase 2 | 30 | MedImmune LLCINDUSTRY | 0 | Sep 5, 2008 | clinicaltrials |
| NCT00415155 | A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 1 / Phase 2 | 60 | Eli Lilly and CompanyINDUSTRY | 4 | Aug 29, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Nov 24, 2009source: clinicaltrials